The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

Program Description

Transthyretin-mediated amyloidosis (ATTR) is a rare yet severe disease caused by genetic abnormalities and can be either hereditary or spontaneous (wild type), where amyloid protein is misfolded and deposited throughout the body with damaging effects. Diagnosis of ATTR may be difficult due to symptom overlap with other conditions, as well as organ system damage including cardiomyopathy, renal failure, and neuropathy, among others. This disease historically is best treated by liver transplant, as this removes the source of affected amyloid; however, recently approved disease-modifying medications have expanded the options for ATTR-polyneuropathy and ATTR-cardiomyopathy. Pharmacists must be aware of signs and symptoms of ATTR to prevent misdiagnosis or delayed diagnosis in patients living with ATTR, as well as make therapy decisions, highlighting the importance of a multidisciplinary care team to improve access to new therapies. This activity will provide an overview of ATTR, the multisystem burden, and key markers of disease progression. Current guidelines and treatment options available for ATTR will be reviewed, including differences in mechanisms of action. Participants in this activity will be better equipped to face the challenges presented by ATTR, as well as make competent recommendations and decisions to improve the diagnosis and treatment of patients living with ATTR.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: May 30, 2024
Expiration date: August 2, 2025
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate among the types of amyloidosis for individualized care considerations
• Explain how transthyretin-mediated amyloidosis therapies may be utilized in treatment while considering efficacy and safety data
• Apply treatment strategies to reduce costs and mitigate racial and gender disparities

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-153-H01-P. The activity is available for CE credit through August 2, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Sami Khella, MD, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Eidos Therapeutics, Pfizer, Medscape

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Medical reviewer Khalid M. Kamal, MPharm, PhD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: EMD Serono, Cerevel Therapeutics
Consultant: Cytle, Pfizer

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms